B vitamins play a key role in managing homocysteine and supporting heart health. Based on this study, Vitamin B could be a ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

Resistant hypertension, especially for prolonged periods, is accompanied by a substantial increase in the overall risk of cardiovascular and renal events, owing to the common coexistence of other ...

The scope of resistant hypertension has not been quantified, but clinical trials suggest it may affect up to 30 percent of people with high blood pressure.

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 : 1159–1164.

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...